Healthcare / Elderly CareUS
← Sticker Wall
JOURNEY · DETAIL
BGI's Wang Jian: From sent-down youth to China representative for the Human Genome Project, the genetic empire that started with SARS sequencing
Founded: Wang Jian · BGI Group (华大基因)
JOURNEY
Key Fields
FIELD STAMPSIndustryHealthcare / Elderly Care
RegionChina
ScaleMid-size
ChannelOther
Origin
Wang Jian developed an interest in life sciences during his years as a sent-down youth, later entering the medical and scientific research systems. Seizing the opportunity in 1999 for China to undertake 1% of the sequencing task for the Human Genome Project, he founded BGI in Beijing. According to public disclosures, BGI's revenue was only 343 million RMB in 2009, climbing to 1.037 billion RMB by 2010. He viewed genetic data as a strategic resource, utilizing an enterprise mechanism to undertake national-level scientific research tasks.
Milestones
1999
Inception Turning Point
In 1999, Wang Jian and other founders self-funded the establishment of BGI in Beijing, proactively applying to undertake 1% of China's sequencing task for the Human Genome Project. This decision bound BGI to national scientific research credibility from its inception, but also brought skepticism from peers due to equipment and funding shortages; the founders even mortgaged personal assets to keep the laboratory running.
2003
SARS Sequencing Pivot
In 2003, BGI took the lead domestically in completing the whole-genome sequencing of the SARS virus and rapidly developed detection kits, transforming BGI from a research institution into a key supplier for the public health emergency response system. This campaign helped BGI secure government trust and subsequent orders, but also exposed organizational shortcomings in production and distribution.
2010
Illumina Equipment Acquisition Turning Point
In 2010, BGI made a one-time purchase of 128 high-throughput sequencers from Illumina, investing over 100 million USD in an attempt to drive down sequencing costs through economies of scale and become one of the world's largest sequencing service providers. This high-stakes gamble led to a surge in production capacity, but also made BGI deeply dependent on US suppliers, planting the risk of future chokeholds on equipment and technology.
2013
Complete Genomics Acquisition Pivot
In 2013, BGI acquired US sequencer manufacturer Complete Genomics for 117.6 million USD in an attempt to shake off its equipment dependence on Illumina and achieve independent sequencer manufacturing. Following the acquisition, BGI launched homegrown sequencing platforms, but also encountered US regulatory scrutiny and core talent drain, making the initial commercialization of independent equipment bumpy.
2017
A-share IPO Growth
In 2017, BGI listed on the ChiNext board of the Shenzhen Stock Exchange, with its market capitalization briefly exceeding 100 billion RMB that year and Wang Jian's personal net worth surging. The IPO brought capital expansion, but the company subsequently faced market skepticism due to insufficient R&D investment, a single core business, and reliance on government subsidies, entering a long period of stock price volatility.
2020
FireEye Laboratories PMF
After the outbreak of the COVID-19 pandemic, BGI rapidly launched nucleic acid testing kits and deployed FireEye laboratories, establishing dozens of labs across China and multiple overseas countries, becoming one of the institutions with the largest COVID-19 testing capacity globally. In 2020, BGI's revenue grew by over 200% year-on-year, but heavy reliance on pandemic orders laid hidden troubles for post-pandemic growth exhaustion.
2021
Post-Pandemic Contraction Failure
In 2021, as the global pandemic eased, the demand for COVID-19 testing dropped off a cliff, leading to a sharp contraction in BGI's revenue and profits. By 2023, company performance remained sluggish, FireEye laboratories faced closures or transformation, and while Wang Jian publicly insisted on long-termism in life sciences, the capital market remained skeptical of post-pandemic strategies, causing the stock price to pull back significantly from its peak.
Turning Points
- Self-funded the establishment of BGI in 1999, securing China's 1% sequencing task for the Human Genome Project and completing the identity transition from an individual researcher to a national strategic supplier.
- Invested over 100 million USD to purchase 128 Illumina sequencers in 2010, trading scale for cost and securing a leading position in global sequencing services.
- Acquired Complete Genomics for 117.6 million USD in 2013, initiating the path toward independent domestic sequencers.
- Rapidly replicated FireEye laboratories in 2020, utilizing the public health crisis to achieve global capacity expansion.
Failures & Pitfalls
- Faced US regulatory pressure and core talent drain after acquiring Complete Genomics in 2013, resulting in low market acceptance during the early commercialization of domestic sequencers.
- Post-pandemic COVID-19 testing demand dropped precipitously, leading to massive closures of FireEye laboratories, a sharp plunge in revenue and profits, and an unclear post-pandemic transformation direction.
- Post-IPO over-reliance on government subsidies and a single business line, with R&D investment remaining low as a proportion for a long time, leading to the capital market labeling the company as hollowing out.
关键成功要素
- Leveraging enterprise mechanisms to undertake national-level scientific research tasks, binding national credit to acquire startup resources.
- Building barriers for government orders through rapid sequencing and kit development during public health crises.
- Breaking through equipment and technology dependencies via massive procurement and overseas acquisitions.
- Demonstrating the rapid replication capability of standardized laboratories through the FireEye laboratory model.
Lessons
- Depending on a single sudden public health demand brings explosive growth, but struggles to build a long-term stable revenue structure.
- Achieving equipment and technology independence requires patience; mergers and acquisitions only solve entry-level problems, and core talent and process accumulation cannot be skipped.
- Pre-IPO government endorsements and post-IPO commercial capabilities are two distinct sets of logic, and the capital market demands higher R&D efficiency.
- Enterprises must lay out their next growth curve ahead of time during boom periods; otherwise, post-pandemic contraction will amplify all management flaws.
Core Data
- 2010年采购测序仪投入：Over 100 million USD (based on public disclosures, independent verification unconfirmed)
- 2017年上市初期市值峰值：Approximately 100 billion RMB (based on public disclosures, independent verification unconfirmed)
- 2020年营收同比增长：Over 200% (based on public disclosures, independent verification unconfirmed)
- 2023年净利和营收下滑：Net profit of approximately 300 million RMB with continued pressure (based on public disclosures, independent verification unconfirmed)
- 2013年收购完整基因组公司金额：117.6 million USD (based on public disclosures, independent verification unconfirmed)
Competitors / Peers
In the domestic market, BGI's main competitors include Berry Genomics, Novogene, and Burning Rock Biotech among gene testing and sequencing service providers. Berry Genomics previously competed with BGI long-term in non-invasive prenatal testing, while Novogene poses a direct threat in research sequencing services. In the international market, Illumina and Thermo Fisher occupy upstream dominance in sequencing equipment and reagents; after achieving equipment independence, BGI gradually carved into their market share, though patents and channels remain major obstacles.